Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

16374

Sigma-Aldrich

4-Bromobenzenesulfonamide

≥99.0% (T)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C6H6BrNO2S
CAS Number:
701-34-8
Molecular Weight:
236.09
Beilstein:
2691657
MDL number:
MFCD00051977
UNSPSC Code:
12352100
PubChem Substance ID:
57647557
NACRES:
NA.22
Pricing and availability is not currently available.

Quality Level

200

Assay

≥99.0% (T)

form

solid

functional group

bromo

SMILES string

NS(=O)(=O)c1ccc(Br)cc1

InChI

1S/C6H6BrNO2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,(H2,8,9,10)

InChI key

STYQHICBPYRHQK-UHFFFAOYSA-N

General description

4-Bromobenzenesulfonamide is a metabolite of ebrotidine, a new H2-receptor antagonist[1].

Application

4-Bromobenzenesulfonamide was used as reagent in preparation of cobalt(III) complexes of N,R-sulfonyldithiocarbimate anion[2]. It was also used in the synthesis of 2-, 3- and 4-(substituted-phenylethynyl)benzenesulfonamides[3].

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
374260/1
377473/1

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E Rozman et al.
Journal of pharmaceutical sciences, 83(2), 252-254 (1994-02-01)
Ebrotidine is a new H2-receptor antagonist which exhibits a remarkable ability for gastric mucosal protection. A preliminary metabolic pathway for this compound was proposed and the hypothetic metabolites were synthesized. The presence of ebrotidine and its metabolites ebrotidine S-oxide and
Raymond Anana et al.
Bioorganic & medicinal chemistry, 14(15), 5259-5265 (2006-04-26)
A group of regioisomeric phenylethynylbenzenesulfonamides possessing a COX-2 SO2NH2 pharmacophore at the para-, meta- or ortho-position of the C-1 phenyl ring, in conjunction with a C-2 substituted-phenyl (H, OMe, OH, Me, F) group, were synthesized and evaluated as inhibitors of
Gloria Uccello-Barretta et al.
Bioorganic & medicinal chemistry, 12(2), 447-458 (2004-01-16)
NMR spectroscopic and molecular modelling methods have been employed to describe the complexation of trans-N-4-[N'-(4-chlorobenzoyl)hydrazinocarbonyl]cyclohexylmethyl-4-bromobenzenesulfonamide, a new chemotype of NPY-5 antagonist, and beta-cyclodextrin, revealing the coexistence of two different kinds of 1:1 complexes where conformational changes of the guest compound
S Sentellas et al.
Electrophoresis, 22(1), 71-76 (2001-02-24)
This paper illustrates the possibilities of chemometric methods in the resolution and quantification of various compounds in overlapping peaks from capillary electrophoresis. Ebrotidine and most of its metabolites were efficiently separated by capillary zone electrophoresis (CZE) in a fused-silica capillary.
Preparation of novel cobalt (III) complexes with dithiocarbimates derived from sulfonamides.
Oliveira MRL and Bellis VMD.
Transition Metal Chemistry, 24(2), 127-130 (1999)

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service